269 related articles for article (PubMed ID: 33674239)
1. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
2. A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy.
Wang K; Tseng CY; Li Z; White C; Wang B; Levine BL; Fesnak AD
Cytotherapy; 2023 Dec; 25(12):1370-1379. PubMed ID: 37747394
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
Harrison RP; Zylberberg E; Ellison S; Levine BL
Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
[TBL] [Abstract][Full Text] [Related]
4. Capacity planning in a decentralized autologous cell therapy manufacturing network for low-cost resilience.
Li J; White CC
Flex Serv Manuf J; 2023; 35(2):295-319. PubMed ID: 36373023
[TBL] [Abstract][Full Text] [Related]
5. Cost of decentralized CAR T-cell production in an academic nonprofit setting.
Ran T; Eichmüller SB; Schmidt P; Schlander M
Int J Cancer; 2020 Dec; 147(12):3438-3445. PubMed ID: 32535920
[TBL] [Abstract][Full Text] [Related]
6. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
Gye A; Lourenco RA; Goodall S
Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
[TBL] [Abstract][Full Text] [Related]
7. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
8. Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges.
Orentas RJ; Dropulić B; de Lima M
Semin Hematol; 2023 Jan; 60(1):20-24. PubMed ID: 37080706
[TBL] [Abstract][Full Text] [Related]
9. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India.
Palani HK; Arunachalam AK; Yasar M; Venkatraman A; Kulkarni U; Lionel SA; Selvarajan S; Korula A; Abraham A; George B; Adair JE; Orentas R; Dropulic B; Mathews V
Bone Marrow Transplant; 2023 Feb; 58(2):160-167. PubMed ID: 36347999
[TBL] [Abstract][Full Text] [Related]
10. [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].
Köhl U; Abken H
Internist (Berl); 2021 Apr; 62(4):449-457. PubMed ID: 33590292
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
12. Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform.
Trainor N; Purpura KA; Middleton K; Fargo K; Hails L; Vicentini-Hogan M; McRobie C; Daniels R; Densham P; Gardin P; Fouks M; Brayer H; Malka RG; Rodin A; Ogen T; Besser MJ; Smith T; Leonard D; Bryan A
Cytotherapy; 2023 Dec; 25(12):1349-1360. PubMed ID: 37690020
[TBL] [Abstract][Full Text] [Related]
13. Autologous CAR T-cell therapies supply chain: challenges and opportunities?
Papathanasiou MM; Stamatis C; Lakelin M; Farid S; Titchener-Hooker N; Shah N
Cancer Gene Ther; 2020 Nov; 27(10-11):799-809. PubMed ID: 31932694
[TBL] [Abstract][Full Text] [Related]
14. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
15. Expanding access to CAR T cell therapies through local manufacturing.
Elsallab M; Maus MV
Nat Biotechnol; 2023 Dec; 41(12):1698-1708. PubMed ID: 37884746
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing innovation to drive down cell therapy costs.
Khang M; Suryaprakash S; Kotrappa M; Mulyasasmita W; Topp S; Wu J
Trends Biotechnol; 2023 Oct; 41(10):1216-1219. PubMed ID: 37236813
[TBL] [Abstract][Full Text] [Related]
18. Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Snyder S; Albertson T; Garcia J; Gitlin M; Jun MP
Adv Ther; 2021 Aug; 38(8):4541-4555. PubMed ID: 34279805
[TBL] [Abstract][Full Text] [Related]
19. Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model.
Sohn H; Kasaie P; Kendall E; Gomez GB; Vassall A; Pai M; Dowdy D
BMC Med; 2019 Aug; 17(1):155. PubMed ID: 31382959
[TBL] [Abstract][Full Text] [Related]
20. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
